Investor Relations

Celgene Corporation and its subsidiaries (collectively "we", "our" or "us") is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. Our primary commercial stage products include REVLIMID^®, VIDAZA^®, THALOMID^® (inclusive of Thalidomide Celgene^® and Thalidomide Pharmion^®), ABRAXANE^®, whi... More >>

Date Title   05/10/12 New England Journal of Medicine Reports on Three Phase III REVLIMID® (lenalidomide) Trials in Patients with Newly Diagnosed Multiple Myeloma Consistent progression-free survival improvement shown with continuous lenalidomide therapy in elderly patients not eligible for transplant and as maintenance therapy in patients following autologous stem cell transplant BOUDRY, Switzerland--(BUSINESS WIRE)--May. 10, 2012-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that results from three phase III studies evaluating the use of cont...  05/07/12 Celgene Corporation Announces Appointment of Thomas M. Moriarty as General Counsel SUMMIT, N.J.--(BUSINESS WIRE)--May. 7, 2012-- Celgene Corporation (NASDAQ: CELG) today announced the appointment of Thomas M. Moriarty as General Counsel and Corporate Secretary. In this position, he will be responsible for global legal strategy at Celgene and will serve on the company’s Management Committee. Mr. Moriarty joins Celgene from Medco Health Solutions where he directed all legal, regulatory, public policy and corporate governance ...  05/04/12 Celgene Corporation to Present at Two Upcoming Investor Conferences SUMMIT, N.J.--(BUSINESS WIRE)--May. 4, 2012-- Celgene Corporation (NASDAQ: CELG) announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the Company’s Web site at www.celgene.com. Celgene management will provide an overview of the Company. Tuesday, May 8, 2012 Celgene will present at the Baird 2012 Growth Stock Conference at 12:20 p.m. ET. ...  04/26/12 Celgene Reports First Quarter 2012 Operating and Financial Results -- Non-GAAP Net Product Sales of $1.25 Billion, Increased 17 Percent Y/Y -- Non-GAAP Total Revenue of $1.27 Billion, Increased 15 Percent Y/Y -- Non-GAAP Diluted Earnings Per Share of $1.08, Increased 30 Percent Y/Y -- 2012 Revenue and Earnings Guidance Reaffirmed SUMMIT, N.J., Apr 26, 2012 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) reported Non-GAAP net product sales ...

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Celgene Corp. posts new information to the site. Just enter your e-mail address and click Submit.